Geneius has developed an innovative, market driven business model for financing the development of Biotechnology products. Our approach aligns the interests of all parties and improves transparency, thereby shortening duration and increasing returns while lowering risk for investors.

Geneius creates a differentiated competitive advantage by efficiently bridging the gap between attractive late stage technologies and Pharma.

Geneius believes that this proprietary business model has the potential to transform the biotech and pharmaceutical industries and will result in a sustainable pipeline of innovative outcome-focused products which both improve and lower the overall cost of healthcare.

Geneius' business intent is that Geneius and Pharma will jointly pursue selected treatment categories under a ‘build-operate-transfer’ model. This approach effectively provides an aligned outsourced development organization.
Product development and clinical trials are designed with the end-product label as the primary objective. This approach should result in higher success rates and reduced time to market.